Mechanisms of action of valproate: A commentatory

Neurochemistry International

Volumn 37, Issue 2-3, 2000, Pages 103-110

  Johannessen, Cecilie U ^a  

^a NORWEGIAN DEFENCE RESEARCH ESTABLISHMENT FFI   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

OXOGLUTARATE DEHYDROGENASE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN HOMOGENATE; BRAIN METABOLISM; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EPILEPSY; GABAERGIC TRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; REVIEW; TREATMENT INDICATION;

ANIMALIA;

EID: 0034257051     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(00)00013-9     Document Type: Article

References (82)

1. Adkinson K.D., Shen D.D. Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. Journal of Pharmacology and Experimental Therapeutics. 276:1996;1189-1200.
2. Albus H., Williamson R. Electrophysical analysis of the action of valproate on pyramidal neurons in the rat hippocampal slice. Epilepsia. 39:1998;124-139.
3. Aman M.G., Werry J.S., Paxton J.W., Turbott S.H. Effect of sodium valproate on psycomotor perforamnce in children as a function of dose, fluctuations in concentration, and diagnosis. Epilepsia. 29:1987;115-124.
4. Anlezark G., Horton R.W., Meldrum B.S., Sawaya C.B. Anticonvulsant action of ethanolamine-o-sulphate and di-n-propylacetate and the metabolism of γ-aminobutyric acid (GABA) in mice with audiogenic seizures. Biochemical Pharmacology. 25:1976;413-417.
5. Bailie T.A., Sheffels P.A. Valproic acid, chemistry and biotransformation. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. 4th ed. 1995;589-604 Raven Press Ltd, New York.
6. Baldino F., Geller H.M. Effect of sodium valproate on hypothalamic neurons in vivo and in vitro. Brain Research. 219:(1):1981;231-237.
7. Bolanos J., Medina J. Evidence of stimulation of the γ-aminobutyric acid shunt by valproate and E-δ2-valproate in neonatal rat brain. Molecular Pharmacology. 43:1993;487-490.
8. Calabrese J.R., Markowitz P., Kimmel S.E., Wagner S.C. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. Journal of Clinical Psychopharmacology. 12:1992;53S-56S.
9. Chapman A.G. Valproate and myoclonus. Fahn S., Mardsen C.D., Van Woert M.H. Advances in Neurology. vol. 43:1986;661-674 Raven Press Ltd, New York.
10. 14C]glucose into amino acids. Neurochemical Research. 7:1982;1089-1109.
11. Chapman A.G., Riley K., Evans M.C., Meldrum B.S. Anticonvulsant activity of intracerebroventricularly administered valproate and valproate analogues. A dosedependent correlation with changes in brain aspartate and GABA levels in DBA/2 mice. Biochemical Pharmacology. 33:1984;1459-1463.
12. Crowder J.M., Bradford H.F. Common anticonvulsants inhibit Ca2+ uptake and amino acid neurotransmitter release in vitro. Epilepsia. 28:1987;378-382.
13. Cutrer F.M., Moskowitz M.A. Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache. 36:1996;579-585.
14. Dixon J.F., Hokin L.E. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-triphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Proceedings of the Natural Academy of Science USA. 94:1997;4757-4760.
15. Fariello R.G., Varasi M., Smith M.C. Valproic acid, mechanisms of action. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. 4th ed. 1995;581-588 Raven Press Ltd, New York.
16. Farrant M., Webster R.A. Neuronal activity, amino acid concentration and amino acid release in the substantia nigra of the rat after sodium valproate. Brain Research. 504:1989;49-56.
17. +]o in the hippocampal slice. Brain Research. 386:1986;1-11.
18. Freeman W.T., Clothier J.L., Pazzaglia P., Lesem M.D., Swann A.C. A double-blind comparison of valproate and lithium in the treatment of acute mania. American Journal of Psychiatry. 149:1992;108-111.
19. Frey H.H., Löscher W. Di-n-propyletic acid-profile of anticonvulsant ativity in mice. Arzneimittelforschung. 26:1976;299-301.
20. 15O water positron emission tomography study. Epilepsia. 37:1996;515-521.
21. Gale K. Role of the substantia nigra in GABA-mediated anticonvulsant actions. Advances in Neurology. 44:1986;343-364.
22. Gean P.W. Valproic acid suppresses thesynaptic response mediated by the NMDA receptors in rat amygdalar slices. Brain Research Bulletin. 33:1994;333-336.
23. Geddes J.W., Wood J.D. Changes in the amino aicd content of nerve endings (synaptosomes) induced by drugs that alter the metabolism of glutamate and γ-aminobutyric acid. Journal of Neurochemistry. 42:1983;16-24.
24. Ghose K., Niven B. Prophylactic sodium valproate therapy in patients with drug-resistant migraine. Method Findings in Experimental and Clinical Pharmacology. 20:1998;353-359.
25. Godin Y., Heier L., Mark J., Mandel P. Effects of di-n-propylacetate, an anticonvulsant compound, on GABA metabolism. Journal of Neurochemistry. 16:1969;869-873.
26. Gram L., Larsson O.M., Johnsen A.H., Schousboe A. Effects of valproate, vigabatrin and amniooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons. Epilepsy Research. 2:1988;87-95.
27. Griffith W.H., Taylor L. Sodium valproate decreases synaptic potentiation and epileptiform activity in hippocampus. Brain Research. 474:1988;155-164.
28. Gundersen V., Chaudry F.A., Bjaalie J.G., Fonnum F., Ottersen O.P., Storm-Mathisen J. Synaptic vesicular localization and exocytosis of L-aspartate in excitatory nerve terminals: a quantitative immunogold analysis in rat hippocampus. Journal of Neuroscience. 18:1998;6059-6070.
29. Hariton C., Ciesielsky S., Simler S., Valli M., Jadot G., Gobaille S., Mesdijan E., Mandel P. Distribution of sodium valproate and GABA metabolism in CNS of the rat. Biopharmaceutics and Drug Disposition. 5:1984;409-414.
30. Hassel B., Sonnewald U. Selective inhibition of the tricarboxylic acid cycle of GABAergic neurons with 3-nitropropionic acid in vivo. Journal of Neurochemistry. 65:1995;1-8.
31. Hassel B., Johannessen C.U., Sonnewald U., Fonnum F. Quantification of the GABA shunt and the importance of the GABA shunt versus the 2-oxoglutarate dehydrogenase pathway in GABAergic neurons. Journal of Neurochemistry. 71:1998;1511-1518.
32. Hayes S.G. Long-term use of valproate in primary psychiatric disorders. Journal of Clinical Psychiatry. 50:1989;35S-39S.
33. Horton R.W., Anlezark G.M., Sawaya M.C., Meldrum B.S. Monoamine and GABA metabolism and the anticonvulsant action of di-n-propylacetate and ethanolamine-O-sulphate. European Journal of Pharmacology. 41:1977;387-397.
34. Iadarola M.J., Gale K. Dissociation between drug-induced increases in nerve terminal and non-nerve terminal pools of GABA in vivo. European Journal of Pharmacology. 59:1979;125-129.
35. Jacobsen F.M. Low-dose valproate: a new treatment for cyclothymia, mild rapid-cycling disorders, and premenstrual syndrome. Journal of Clinical Psychiatry. 54:1993;229-234.
36. Keck P.E. Jr, Mcelroy S.L., Nemeroff C.B. Anticonvulsants in the treatment of bipolar disorder. Journal of Neuropsychiatry and Clinical Neuroscience. 4:1992;395-405.
37. Keck P.E. Jr, McElroy S.L., Tugrul K.C., Bennett J.A. Valproate oral loading in the treatment of acute mania. Journal of Clinical Psychiatry. 54:1993;305-308.
38. Keck P.E. Jr, McElroy S.L., Tugril K.C., Bennett J.A., Smith J.M.R. Antiepileptic drugs for the treatment of panic disorder. Neuropsychobiology. 27:1993;150-153.
39. Kukino K., Deguchi T. Anticonvulsant activity and effects of sodium dipropylacetate on cerebral 5-hydroxytryptamine and gamma-aminobutyric acid in reserpinized mice. Chemical Pharmacological Bulletin. 26:1978;3551-3555.
40. Kusumakar V., Yatham L.N., Haslam D., Parikh S.V., Matte R., Silverstone P.H., Sharma V. Treatment of mania, mixed state, and rapid cycling. Canadian Journal of Psychiatry. 42:(Suppl. 2):1997;79S-86S.
41. Larsson O.M., Gram L., Schousboe I., Schousboe A. Differential effects of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurons and astrocytes. Neuropharmacology. 25:1986;617-625.
42. Leiderman D.B., Balish M., Bromfield E.B., Theodore W.H. Effect of valproate on human cerebral glucose metabolism. Epilepsia. 32:1991;417-422.
43. Löscher W. Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA. Journal of Neurochemistry. 34:1980;1603-1608.
44. Löscher W. Frey H.H., Janz D. Antiepileptic Drugs. 1985;507-536 Springer-Verlag, Berlin.
45. Löscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Research. 501:1989;198-203.
46. Löscher W. Effect of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochemical Research. 18:1993;485-502.
47. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanism of action. Progress in Neurobiology. 58:1999;31-59.
48. Löscher W., Hörstermann D. Differential effects of vigabatrin, γ-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma. Nauyn-Schmiedeberg's Archives of Pharmacology. 349:1994;270-278.
49. Löscher W., Schmidt D. Increase of human plasma GABA by sodium valproate. Epilepsia. 21:1980;611-615.
50. Löscher W., Vetter M. Relationship between drug-induced increases of GABA levels in discrete brain areas and different pharmacological effects in rats. Biochemical Pharmacology. 33:1985;1907-1914.
51. Luder A.S., Parks J.K., Frerman F., Parker W.D. Inactivation of beef brain α-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. American Society of Clinical Investigations. 86:1990;1574-1581.
52. Maitre M., Hechler V., Vayer P., Gobaille S., Cash C.D., Schmitt M., Borguignon I.J. A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. Journal of Pharmacology and Experimental Therapeutics. 255:1990;657-663.
53. McElroy S.L., Keck P.E. Experience with valproate in affective disorders. Modigh K., Robak O.H., Vestergaard P. Anticonvulsants in Psychiatry. 1994;57-72 Wrightson Biomedical Publishing Ltd, UK.
54. McElroy S.L., Keck P.E. Jr, Tugrul K.C., Bennett J.A. Valproate as a loading treatment in acute mania. Neuropsychobiology. 27:1993;146-149.
55. McIlwain H., Bachelard H.S. Biochemistry and the Central Nervous System. 5th ed. 1985;Churchill Livingstone, New York. pp. 179.
56. McLean M.J., MacDonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. Journal of Pharmacology and Experimental Therapeutics. 237:1986;1001-1011.
57. Meshki Baf M.H., Subhash M.N., Madepalli Lakshamana, Ksridara Rama Rao B.S. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochemistry International. 1:1994;67-72.
58. Mitsikostas D., Polychronidis I. Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial. Functional Neurology. 12:1997;267-276.
59. Nau W., Löscher W. Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse. Journal of Pharmacology and Experimental Therapeutics. 220:1982;654-659.
60. Nilsson M., Hansson E., Ronnback L. Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures. Neurochemical Research. 17:1992;327-332.
61. Paulsen R.E., Fonnum F. Regulation of transmitter GABA synthesis and metabolism illustrated by the effect of vinyl-GABA and hypoglycemia. Journal of Neurochemistry. 50:1988;1151-1157.
62. Petroff O.A.C., Rothman D.L., Behar K.L., Hyder F., Mattson R.H. Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Seizure. 8:1999;120-127.
63. Phillips N.I., Fowler L.J. The effects of sodium valproate on γ-aminobutyrate metabolism and behavior in naïve and ethanolamine-O-sulphate pretreated rats and mice. Biochemical Pharmacology. 31:1982;2257-2261.
64. Price D.J. Intravenous valproate: experience in neurosurgery. Chadwick D. Fourth International Symposium on Sodium Valproate and Epilepsy. 1989;197-203 Royal Society of Medicine Services, London.
65. Puzynski S., Klociewicz L. Valproic acid amide as a prophylactic agent in the treatment of affective and achizoaffective disorders. Psychopharmacological Bulletin. 20:1984;151-159.
66. Sarhan S., Seiler N. Metabolic inhibitors and subcellular distribution of GABA. Journal of Neuroscience Research. 4:1979;399-421.
67. Sawaya C.B., Horton R.W., Meldrum B.S. Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA. Epilepsia. 16:1975;649-655.
68. Schechter P.J., Tranier Y., Grove J. Effect of n-dipropylacetate on amino acid concentrations in mouse brain: correlations with anti-convulsant activity. Journal of Neurochemistry. 31:1978;1325-1327.
69. Schousboe I., Bro B., Schousboe A. Intramitochondrial localization of the 4-aminobutyrate-2-oxoglutarate transaminase from ox brain. Biochemical Journal. 162:1977;303-307.
70. Silberstein S.D. Divalproex sodium in headache: literature review and clinical guidelines. Headache. 36:1996;547-555.
71. Slater G.E., Johnston D. Sodium valproate increases potassium conductance in Aplysia neurons. Epilepsia. 19:1978;379-384.
72. Slevin J.T., Ferrara L.P. Chronic valproic acid therapy and synaptic markers of amino acid neurotransmission. Neurology. 35:1985;728-731.
73. Snead O.C. Gamma-hydroxybutyric acid in subcellular fractions of rat brain. Journal of Neurochemistry. 48:1987;196-201.
74. Stoll A.L., Banov M., Kolbrener M., Mayer P.V., Tohen M., Strakowski S.M., Castillo J., Suppes T., Cohen B.M. Journal of Clinical Psychopharmacology. 14:1994;311-313.
75. Thomas A.B., Mathews G.C., Ferrendelli J.A. Mechanisms of action of antiepileptic drugs. Wyllie E. The Treatment of Epilepsy: Principles and Practice. 2nd ed. 1996;700-711 Williams & Wilkins, Baltimore.
76. Trimble M.R., Thompson P.J. Sodium valproate and cognitive function. Epilepsia. 25:(Suppl. 1):1984;S60-S64.
77. Van den Berg C.J., Kok P., Voskuyl R.A. Valproate and sodium currents in culture hippocampal neurons. Experimental Brain Research. 93:1993;279-287.
78. Van der Laan J.W., de Boer T., Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. Journal of Neurochemistry. 32:1979;1769-1780.
79. Vayer P., Cash C.D., Maitre M. Is the anticonvulsant mechanism of valproate linked to its interaction with the cerebral γ-hydroxybutyrate system? Trends in Pharmacological Science. 9:1988;127-129.
80. Whittle S.R., Turner A.J. Effects of the anticonvulsant sodium valproate on γ-aminobutyrate and aldehyde metabolism in ox brain. Journal of Neurochemistry. 37:1978;1453-1459.
81. Yamamoto R., Yanagrita T., Kobayashi H., Yokoo H., Wada A. Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. Journal of Neurochemistry. 68:1997;1655-1662.
82. Zeise M.L., Kasparow S., Zieglegänzberger W. Valproate supresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Research. 544:1991;345-348.